CoChat

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer

Open access
Beglyarova, Natalya, Banina, Eugenia, Zhou, Yan, Mukhamadeeva, Ramilia, Andrianov, Grigorii, Bobrov, Egor, Lysenko, Elena, Skobeleva, Natalya, Gabitova, Linara, Restifo, Diana, Pressman, Max, Serebriiskii, Ilya G., Hoffman, John P., Paz, Keren, Behrens, Diana, Khazak, Vladimir, Jablonski, Sandra A., Golemis, Erica A., Weiner, Louis M., Astsaturov, Igor · 2016 · Clinical Cancer Research
Cited by 61

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Purpose: Even when diagnosed prior to metastasis, pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with almost 90% lethality, emphasizing the need for new therapies optimally targeting the tumors of individual patients. Experimental Design: We first developed a panel of new physiologic models for study of PDAC, expanding surgical PDAC tumor samples in culture using short-term culture and conditional reprogramming with the Rho kinase inhibitor Y-27632, and creating matched patient-derived xenografts (PDX). These were evaluated for sensitivity to a large panel of clinical agents, and promising leads further evaluated mechanistically. Results: Only a small minority of tested agents was cytotoxic in minimally passaged PDAC cultures in vitro. Drugs interfering with protein turnover and transcription were among most cytotoxic. Among transcriptional repressors, triptolide, a covalent inhibitor of ERCC3, was most consistently effective in vitro and in vivo causing prolonged complete regression in multiple PDX models resistant to standard PDAC therapies. Importantly, triptolide showed superior activity in MYC-amplified PDX models and elicited rapid and profound depletion of the oncoprotein MYC, a transcriptional regulator. Expression of ERCC3 and MYC was interdependent in PDACs, and acquired resistance to triptolide depended on elevated ERCC3 and MYC expression. The Cancer Genome Atlas analysis indicates ERCC3 expression predicts poor prognosis, particularly in CDKN2A-null, highly proliferative tumors. Conclusions: This provides initial preclinical evidence for an essential role of MYC–ERCC3 interactions in PDAC, and suggests a new mechanistic approach for disruption of critical survival signaling in MYC-dependent cancers. Clin Cancer Res; 22(24); 6153–63. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-0149

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 61

Metadata

Authors
Beglyarova, N., Banina, E., Zhou, Y., Mukhamadeeva, R., Andrianov, G., Bobrov, E., Lysenko, E., Skobeleva, N., Gabitova, L., Restifo, D., Pressman, M., Serebriiskii, I. G., Hoffman, J. P., Paz, K., Behrens, D., Khazak, V., Jablonski, S. A., Golemis, E. A., Weiner, L. M., & Astsaturov, I.
Venue
Clinical Cancer Research
Published
2016-12-15
Volume
22
Issue
24
Pages
6153-6163
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2466451217
Cited by
61
References
12
FWCI
3.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-0149
The paper
Beglyarova, N., Banina, E., Zhou, Y., Mukhamadeeva, R., Andrianov, G., Bobrov, E., Lysenko, E., Skobeleva, N., Gabitova, L., Restifo, D., Pressman, M., Serebriiskii, I. G., Hoffman, J. P., Paz, K., Behrens, D., Khazak, V., Jablonski, S. A., Golemis, E. A., Weiner, L. M., & Astsaturov, I. (2016). Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-0149

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.